Article PDF first page preview

Article PDF first page preview

Introduction: Secretory immunoglobulin-A (SIgA), which is not produced perinatally, binds bacteria enhancing mucosal immunity. Higher levels of intestinal bacteria bound by SIgA are protective against necrotizing enterocolitis. Transamniotic fetal immunotherapy (TRAFIT) has previously been used to deliver SIgA to the fetal digestive tract, however with unclear functional impact. We sought to determine whether SIgA administered via TRAFIT could functionally bind intestinal bacteria postnatally. Methods: Fetuses (n=38) from four dams underwent intra-amniotic injections of human SIgA on gestational-day 19 (E19; term=E22-E23). After spontaneous delivery, pups were survived for 1-2 days postnatally before intestinal contents were procured and submitted to flow cytometry. Specimens were stained for bacteria (Syto-GFP) and human-SIgA (PE) to prevent cross-reactivity with maternal rat SIgA. Results: Overall survival was 94.7% (36/38). SIgA-bacterial complexes were identified in all samples at all time points showing significantly higher positive PE events than unstained controls (p=0.03-0.05). The proportion of bacteria bound by IgA decreased daily, from 45.6% to 29.9% bound at 4 to 6 days post-TRAFIT, respectively (overall p=0.05). Conclusions: Transamniotic fetal immunotherapy with secretory-IgA leads to functionally IgA-bound bacteria into the postnatal period and may be a novel strategy for enhancing early mucosal immunity, potentially protecting the neonate against necrotizing enterocolitis.

Journal Section:
Basic Science and Pathophysiology
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.